Citi Reiterates Sell Rating on Blueprint Medicines (BPMC) As Co is Acquired
Tweet Send to a Friend
Citi analyst David Lebowitz reiterated a Sell rating and $83.00 price target on Blueprint Medicines (NASDAQ: BPMC).The analyst comments "Blueprint ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
